A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

NCT06555640 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hypertriglyceridemia

Interventions

DRUG: DR10624 Injection
DRUG: Placebo

Sponsor

Zhejiang Doer Biologics Co., Ltd.